• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用动态 [F]THK5317 PET 进行 tau 病理学成像和参考区域的自动提取的最佳时机。

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET.

机构信息

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Medical Physics, Uppsala University Hospital, Uppsala, Sweden.

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

出版信息

Neuroimage Clin. 2019;22:101681. doi: 10.1016/j.nicl.2019.101681. Epub 2019 Jan 22.

DOI:10.1016/j.nicl.2019.101681
PMID:30710871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6357848/
Abstract

[F]THK5317 is a PET tracer for in-vivo imaging of tau associated with Alzheimer's disease (AD). This work aimed to evaluate optimal timing for standardized uptake value ratio (SUVR) measures with [F]THK5317 and automated generation of SUVR-1 and relative cerebral blood flow (R) parametric images. Nine AD patients and nine controls underwent 90 min [F]THK5317 scans. SUVR-1 was calculated at transient equilibrium (TE) and for seven different 20 min intervals and compared with distribution volume ratio (DVR; reference Logan). Cerebellar grey matter (MRI) was used as reference region. A supervised cluster analysis (SVCA) method was implemented to automatically generate a reference region, directly from the dynamic PET volume without the need of a structural MRI scan, for computation of SUVR-1 and R images for a scan duration matching the optimal timing. TE was reached first in putamen, frontal- and parietal cortex at 22 ± 4 min for AD patients and in putamen at 20 ± 0 min in controls. Over all regions and subjects, SUVR-1 correlated best with DVR-1, R = 0.97. High correlation was found between values generated using MRI- and SVCA-based reference (R = 0.93 for SUVR-1; R = 0.94 for R). SUVR allows for accurate semi-quantitative assessment of tau pathology and SVCA may be used to obtain a reference region for calculation of both SUVR-1 and R with 40 min scan duration.

摘要

[F]THK5317 是一种用于阿尔茨海默病(AD)相关 tau 的体内成像的正电子发射断层扫描(PET)示踪剂。本研究旨在评估[F]THK5317 的标准化摄取值比(SUVR)测量的最佳时间,并自动生成 SUVR-1 和相对脑血流(R)参数图像。9 名 AD 患者和 9 名对照者接受了 90 分钟[F]THK5317 扫描。在瞬态平衡(TE)和 7 个不同的 20 分钟间隔计算 SUVR-1,并与分布容积比(DVR;参考 Logan)进行比较。小脑灰质(MRI)用作参考区。实施了监督聚类分析(SVCA)方法,该方法可从动态 PET 体积中自动生成参考区,而无需进行结构 MRI 扫描,以用于计算与最佳时间匹配的扫描持续时间的 SUVR-1 和 R 图像。在 AD 患者中,纹状体、额皮质和顶叶皮质在 22±4 分钟达到 TE,而在对照组中在纹状体中在 20±0 分钟达到 TE。在所有区域和受试者中,SUVR-1 与 DVR-1 相关性最佳,R=0.97。使用 MRI 和 SVCA 基于参考的方法生成的值之间相关性较高(SUVR-1 为 R=0.93;R 为 R=0.94)。SUVR 可用于准确评估 tau 病理学的半定量评估,SVCA 可用于获得参考区,以计算 40 分钟扫描时间的 SUVR-1 和 R。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/6515d09fa9f4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/9b0b63f060eb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/695ceb20f00c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/7c481c8e13ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/58b362813c79/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/f7e3b951fc81/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/e853d3e3ef09/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/6515d09fa9f4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/9b0b63f060eb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/695ceb20f00c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/7c481c8e13ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/58b362813c79/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/f7e3b951fc81/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/e853d3e3ef09/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35f7/6357848/6515d09fa9f4/gr7.jpg

相似文献

1
Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET.使用动态 [F]THK5317 PET 进行 tau 病理学成像和参考区域的自动提取的最佳时机。
Neuroimage Clin. 2019;22:101681. doi: 10.1016/j.nicl.2019.101681. Epub 2019 Jan 22.
2
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.(S)-¹⁸F-THK5117 作为评估 Tau 病理学的 PET 示踪剂的示踪动力学分析。
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.
3
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.Tau放射性配体F-THK-5351和F-THK-5317的体内比较
J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.
4
Comparability of [F]THK5317 and [C]PIB blood flow proxy images with [F]FDG positron emission tomography in Alzheimer's disease.[F]THK5317和[C]PIB血流替代图像与[F]FDG正电子发射断层扫描在阿尔茨海默病中的可比性。
J Cereb Blood Flow Metab. 2017 Feb;37(2):740-749. doi: 10.1177/0271678X16645593. Epub 2016 Jul 20.
5
Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.使用[18F]THK - 5351对认知正常的老年人和阿尔茨海默病患者中tau蛋白积累的动态PET测量。
PLoS One. 2016 Jun 29;11(6):e0158460. doi: 10.1371/journal.pone.0158460. eCollection 2016.
6
Tau PET imaging with F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.阿尔茨海默病患者与健康对照者中 F-PI-2620 的 Tau PET 成像:首例人体研究。
J Nucl Med. 2020 Jun;61(6):911-919. doi: 10.2967/jnumed.119.236224. Epub 2019 Nov 11.
7
Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.采用多模态范式,利用THK5317正电子发射断层扫描(PET)对阿尔茨海默病体内的tau病理进行成像。
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1686-99. doi: 10.1007/s00259-016-3363-z. Epub 2016 Mar 21.
8
Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease.阿尔茨海默病患者脑灌注、葡萄糖代谢和 tau 沉积的纵向解偶联。
Alzheimers Dement. 2018 May;14(5):652-663. doi: 10.1016/j.jalz.2017.11.008. Epub 2017 Dec 19.
9
Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.tau PET 显像与前驱期和阿尔茨海默病痴呆代谢减退的关系的纵向变化。
Mol Psychiatry. 2018 Jul;23(7):1666-1673. doi: 10.1038/mp.2017.108. Epub 2017 May 16.
10
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.在体鉴定和定量研究人类神经纤维缠结 Tau PET 放射性配体 F-MK-6240 从阿尔茨海默病痴呆到年轻对照的变化。
J Nucl Med. 2019 Jan;60(1):93-99. doi: 10.2967/jnumed.118.209650. Epub 2018 May 18.

引用本文的文献

1
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.在结构化的 5 阶段开发框架背景下,THK 家族和 PBB3 皮质 Tau 配体 PET 增加作为阿尔茨海默病生物标志物的临床有效性。
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2086-2096. doi: 10.1007/s00259-021-05277-4. Epub 2021 Mar 15.
2
A novel application of tau PET in the diagnosis of sporadic inclusion body myositis: A case report.tau正电子发射断层扫描在散发性包涵体肌炎诊断中的新应用:一例报告
Medicine (Baltimore). 2020 Jul 31;99(31):e21524. doi: 10.1097/MD.0000000000021524.

本文引用的文献

1
Development of a clinically feasible [C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.开发一种临床可行的[C]PE2I正电子发射断层扫描(PET)方法,用于帕金森综合征的鉴别诊断,该方法可缩短扫描时间并自动提取参考区域。
Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):263-274. eCollection 2017.
2
Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.tau PET 显像与前驱期和阿尔茨海默病痴呆代谢减退的关系的纵向变化。
Mol Psychiatry. 2018 Jul;23(7):1666-1673. doi: 10.1038/mp.2017.108. Epub 2017 May 16.
3
Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by H-THK5117 and H-deprenyl autoradiography.
阿尔茨海默病中海马 H-THK5117 和 H-去甲丙炔苯丙胺放射性自显影可见皮质层状 tau 沉积物和活化星形细胞。
Sci Rep. 2017 Apr 4;7:45496. doi: 10.1038/srep45496.
4
Quantification of Tau Load Using [F]AV1451 PET.使用[F]AV1451 PET 对 Tau 负荷进行定量分析。
Mol Imaging Biol. 2017 Dec;19(6):963-971. doi: 10.1007/s11307-017-1080-z.
5
Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain.单胺氧化酶B抑制剂司来吉兰可降低人脑中F-THK5351的摄取。
Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.
6
Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology.tau病理患者体内F-AV-1451结合定量的建模策略
J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.
7
Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.使用[18F]THK - 5351对认知正常的老年人和阿尔茨海默病患者中tau蛋白积累的动态PET测量。
PLoS One. 2016 Jun 29;11(6):e0158460. doi: 10.1371/journal.pone.0158460. eCollection 2016.
8
Comparability of [F]THK5317 and [C]PIB blood flow proxy images with [F]FDG positron emission tomography in Alzheimer's disease.[F]THK5317和[C]PIB血流替代图像与[F]FDG正电子发射断层扫描在阿尔茨海默病中的可比性。
J Cereb Blood Flow Metab. 2017 Feb;37(2):740-749. doi: 10.1177/0271678X16645593. Epub 2016 Jul 20.
9
Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.采用多模态范式,利用THK5317正电子发射断层扫描(PET)对阿尔茨海默病体内的tau病理进行成像。
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1686-99. doi: 10.1007/s00259-016-3363-z. Epub 2016 Mar 21.
10
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.(S)-¹⁸F-THK5117 作为评估 Tau 病理学的 PET 示踪剂的示踪动力学分析。
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.